Notch is building best-in-class T cell therapies.
We’ve developed a UNiversal T cell derived from induced pluripotent stem cells (iPSCs). Our new UNi-T Cell is an off-the-shelf solution that solves key challenges in adoptive cell therapy.
Unlimited
THERAPEUTIC T CELLS
THERAPEUTIC T CELLS
Latest News
December 9, 2024
A New Era in Cell Therapy
Current CAR-T therapies harvest and genetically modify T cells, patient by patient, and have been transforming the treatment of blood cancers for several years. Compared to small molecules or biologics, a T cell’s behavior makes it an ideal therapeutic – it can expand in response to disease targets, actively penetrate tissues, and persist to monitor for future disease recurrence. However, when approximately six percent of patients in approved indications receive this kind of treatment today-and when there is enormous potential for CAR-T therapies to treat so many more diseases-there’s a problem. And it comes down to commercial potential and cost.
Notch’s iPSC-derived T cell approach, the UNi-T Cell, eliminates the need for the costly and variable modification and manufacture of patient- or donor-sourced cells and allows us to develop persistent and potent cell therapies with patient experience and access in mind. This means our products will be able to provide a uniform, cost effective, and accessible CAR-T option to many more patients.
About Notch
Founded in 2018, Notch is working to maximize the benefits and reach of new generations of cellular immunotherapies.
We have developed our UNi-T Cell derived from induced pluripotent stem cells (iPSCs). This means:
- Our approach is to make T cell therapies more drug-like, with a uniform and consistent off-the-shelf drug product that can be delivered to patients at the time of diagnosis.
- We are developing persistent and potent cell therapies with patient experience and access in mind.
- Our iPSC-derived UNi-T Cells demonstrate durable and robust tumor control.
- Our proprietary, scalable manufacturing approach enables unprecedented cost effectiveness and accessibility for patients.
